生物信息学
极光激酶
生物
系统药理学
计算生物学
转录组
基因
药物重新定位
卵巢癌
癌症研究
虚拟筛选
福克斯M1
靶向治疗
药理学
精密医学
医学
药物发现
基因调控网络
生物信息学
小RNA
激酶
转录因子
基因表达谱
药品
药物开发
癌症
基因组学
个性化医疗
生物网络
系统生物学
植物化学
信号转导
对接(动物)
免疫系统
小桶
作者
Hriddhi Sarker,Md. Ahad Ali,Md Fakhrul Islam,Enam Ahmed,Amlan Ganguly,Md. Nazmul Hasan Zilani
标识
DOI:10.1016/j.jgeb.2026.100745
摘要
Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies, largely because it is often diagnosed late, recurs frequently, and develops resistance to conventional chemotherapy. These challenges emphasize the urgent need for novel and less toxic therapeutic strategies. In this study, we applied an integrative in silico workflow combining transcriptomic analysis, network biology, pan-cancer exploration, and computational drug discovery to identify potential phytochemical inhibitors targeting Aurora kinase A (AURKA) in OC. Differential gene expression analysis of three GEO datasets (GSE14407, GSE18520, and GSE26712) identified common dysregulated genes associated with OC progression. Functional enrichment and regulatory network analyses revealed strong involvement of these genes in cell-cycle regulation, mitotic progression, and cancer-related signaling pathways. Protein-protein interaction analysis identified AURKA as a central hub gene with high network connectivity and strong overexpression across multiple cancer types. Further pan-cancer analyses demonstrated significant associations of AURKA with immune infiltration patterns and recurrent genetic alterations, supporting its therapeutic relevance. After removing duplicates from the 6834 collected phytochemicals, a total of 2046 unique compounds derived from medicinal plants of the Indian subcontinent were screened against the AURKA crystal structure using molecular docking to identify potential inhibitors. Several compounds demonstrated binding affinities comparable to the reference inhibitor Y3M. Subsequent drug-likeness, ADMET, toxicity prediction, molecular dynamics simulation, MM-GBSA binding energy analysis, and quantum mechanical evaluations identified CID-87014 (2-(Hydroxymethyl)anthraquinone) as the most promising candidate. This compound exhibited stable protein-ligand interactions, favorable binding free energy, acceptable predicted pharmacokinetic properties, and balanced electronic stability throughout the analyses. Although the findings are computational and require experimental validation, CID-87014 emerged as a promising lead compound targeting AURKA and may serve as a foundation for future ovarian cancer drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI